Encompass Health (EHC) is back on investor radars after opening Eastside Rehabilitation Hospital in Loganville, Georgia. The 40 bed facility is a joint venture with Piedmont that expands its inpatient rehabilitation footprint in the state.

The recent Georgia hospital opening and new facilities planned in West Virginia come as Encompass Health’s share price, at US$103.35, shows modest momentum, with a 3.04% 90 day share price return but a 12.87% decline in 1 year total shareholder return and stronger gains over 3 and 5 years.

If this kind of expansion story has your attention, it may be a good moment to see what else is taking shape across rehabilitation and healthcare technology by scanning 39 healthcare AI stocks

With shares at US$103.35 and recent returns mixed, Encompass Health appears to be trading at a discount to some valuation estimates, including external price targets and intrinsic value models. Investors may therefore question whether this weakness represents a potential opportunity or whether the market is already appropriately pricing in the company’s prospects.

Most Popular Narrative: 4.2% Overvalued

At a last close of $103.35 versus a narrative fair value of $99.17, Encompass Health sits slightly above the level that the most followed thesis anchors on.

Encompass Health (NYSE: EHC) operates in a corner of healthcare that doesn’t always grab headlines but often determines whether patients truly recover or quietly relapse into the system. As one of the largest providers of inpatient rehabilitation services in the United States, the company focuses on helping patients regain independence after strokes, surgeries, neurological conditions, and complex injuries. In today’s reimbursement-sensitive healthcare environment, outcomes matter more than ever, and that is where Encompass Health’s positioning becomes increasingly interesting.

This narrative leans heavily on the shift from volume to value, patient outcomes, and how sustained earning power interacts with a long term discount rate. It links clinical depth, margin resilience, and disciplined expansion into one valuation story that differs from the recent share price trend.

Result: Fair Value of $99.17 (OVERVALUED)

However, this thesis can be tested quickly if reimbursement pressures increase or if new rehabilitation capacity in key markets begins to weigh on occupancy and pricing power.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle: Multiples Point to a Different Story

While the user narrative pegs fair value at $99.17 and flags Encompass Health as 4.2% overvalued, the market’s own pricing signals look looser. The stock trades on a P/E of 17.3x versus 23x for the wider US Healthcare industry, 15.1x for direct peers, and a fair ratio of 22.2x. This leaves investors weighing valuation cushion against the risk of the gap closing.

Next Steps

Curious whether the mixed signals in this article point to opportunity or risk for you personally? Act while the data is fresh and weigh both sides with 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Encompass Health has you thinking about what else might fit your portfolio, it is worth lining up a few focused screens before the next move in the market.

• Spot potential value opportunities early by checking companies highlighted in 48 high quality undervalued stocks.
• Strengthen your downside protection by reviewing stocks featured in 63 resilient stocks with low risk scores.
• Hunt for future standouts before they appear on everyone’s radar through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.